BCP
VKTX icon

BlackBarn Capital Partners’s Viking Therapeutics VKTX Stock Holding History

BlackBarn Capital Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.75M Buy
+250,000
New +$8.08M 0.82% 21

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

BlackBarn Capital Partners's VKTX Position: Q2 2026 in Review

BlackBarn Capital Partners reduced its Viking Therapeutics (VKTX) stake by 3.5% in Q2 2026, selling an estimated $693K and leaving 600,000 shares worth $23.4M. The position accounts for 1.97% of the portfolio, ranked #13.

BlackBarn Capital Partners first reported a position in VKTX in Q2 2025 and has held it in 5 quarters since. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • BlackBarn Capital Partners held 600,000 shares of Viking Therapeutics worth $23.4M as of Q2 2026.
  • BlackBarn Capital Partners sold 21,450 Viking Therapeutics shares in Q2 2026, an estimated $693K.
  • Viking Therapeutics made up 1.97% of BlackBarn Capital Partners's portfolio in Q2 2026, its #13 holding.
  • BlackBarn Capital Partners first reported a position in Viking Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on BlackBarn Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.